Objective To determine the accuracy of guaiac and immunochemical faecal occult blood tests (FOBTs) for the detection of colorectal cancer in an average-risk screening population. Methods Fifteen electronic databases, the internet, key journals and reference lists of included studies were searched. We included diagnostic accuracy studies that compared guaiac or immunochemical FOBTs with any reference standard, for the detection of colorectal cancer in an average-risk adult population, with sufficient data to construct a 2 Â 2 table.
INTRODUCTION
T he estimated lifetime risk of colorectal cancer (CRC) is 5-6% with almost 50% of CRC patients eventually dying of their disease. 1,2 In England and Wales over 30,000 new cases are diagnosed each year. 3 Mortality from CRC can be reduced by early detection of cancer and removal of adenomas. 4 Randomized controlled trials (RCTs) have shown that annual or biennial screening in asymptomatic people over the age of 50 years using faecal occult blood tests (FOBTs) can reduce CRC mortality by 15-33%. [5] [6] [7] [8] [9] [10] This systematic review was commissioned to evaluate the comparative diagnostic performance of guaiac and immunochemical FOBTs, in the context of a decision to introduce screening for CRC, using FOBT, in the UK. RCTs can provide data on the comparative clinical outcomes of patients undergoing different screening regimens, while diagnostic accuracy studies provide information on the comparative ability of different screening tests to distinguish patients with disease from those without (diagnostic accuracy data). Therefore, diagnostic accuracy data can be considered a reasonable substitute for an RCT comparing tests, where it is combined with good evidence of a prognostic link between the parameter being tested and the disease state of interest and of the availability of an effective intervention. In this instance, a policy decision had already been made to implement FOBT screening in the UK, so that the starting assumption for the review was, by implication, that these conditions were satisfied.
Guaiac FOBTs detect the haem moiety of haemoglobin; the pseudoperoxidase activity of haem releases oxygen from hydrogen peroxide, which reacts with guaiac to form a blue dye. [11] [12] [13] Immunochemical FOBTs use monoclonal or polyclonal antibodies raised against the globin moiety of human haemoglobin, detecting intact human haemoglobin or its very early degradation products. 11, 14 Immunochemical tests can be grouped into several types, including enzyme immuno assay (EIA), reverse passive haemagglutination (RPHA), latex agglutination inhibition assay and latex agglutination assay. Guaiac FOBTs are more comparable. Pooling of data was precluded, for both guaiac and immunochemical FOBTs, due to clinical and statistical heterogeneity. Therefore, the narrative discusses the diagnostic performance of FOBTs according to FOBT type (guaiac or immunochemical).
A UK screening programme has now been implemented, and this paper summarizes the evidence presented in the systematic review commissioned to inform the decision as to which FOBT, or combination of FOBTs, was to be used for the screening of an average-risk UK population. In July 2006, men and women in the UK aged 60-69 years were invited for screening with the guaiac FOBT, Hema-Screen (Alpha Laboratories); it is planned for screening to be repeated every two years. The first phase of the Australian National Bowel Cancer Screening Program started in August 2006, with men and women aged 55 and 65 years being
METHODS
The systematic review was performed in accordance with the Centre for Reviews and Dissemination guidelines, 15 and guidelines on the meta-analysis of diagnostic tests. [16] [17] [18] [19] [20] [21] [22] We search 15 databases for published and unpublished studies, with no language restrictions, up to November 2004. The internet, bibliographies of included studies and systematic reviews, key journals and conference proceedings were also searched. In March 2007, the search was repeated in MEDLINE (including pre-MEDLINE) and EMBASE. Details of the search strategies are reported elsewhere. 23 Diagnostic cohort studies (diagnosis has not been determined prior to recruitment into the study, and all participants undergo both the index test and a reference standard) were eligible if they compared a guaiac and/or immunochemical FOBT with any reference standard, in an average-risk adult population, and had sufficient data to construct a 2 Â 2 table. Diagnostic case-control studies (diagnosis has been determined prior to recruitment into the study; all participants undergo the index test; diagnostic status is the reference standard) were included whether or not the reference standard used to verify disease status was reported. Diagnostic cohorts were derived using data from the screened arm of effectiveness trials if they reported the use of a reference standard after both a positive and negative FOBT, and had a dropout rate less than 15%. Studies evaluating flushable FOBTs, stool DNA markers, or tests for albumin or calprotectin were excluded.
The methodological quality of include studies was assessed using the QUADAS tool. 16 All stages of the review process were conducted in duplicate; disagreements were resolved by consensus, or referral to a third reviewer. Sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio, with 95% confidence intervals (CIs), were calculated for each study, and results presented in ROC space. Data were not pooled where Cochrane Q was o0.05 24 and/or I 2 was >75%. 25, 26 Where >10 studies were included in any pooled group, regression analyses were undertaken to investigate potential sources of observed heterogeneity. Full methods and results are reported elsewhere. 23 
RESULTS
Fifty-nine studies met the inclusion criteria, 23 evaluating guaiac FOBTs, 25 immunochemical FOBTs 50-74 and 10 both. [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] One study evaluated a guaiac and immunochemical FOBT in sequence, but did not report results for the two tests separately. 85 The search in March 2007 identified two further studies (see addendum). 86, 87 
Study quality
The universal use of an appropriate reference standard to exclude disease was a particular issue for studies in this review. Seventeen out of 23 guaiac FOBT studies reported using colonoscopy after a positive FOBT (diagnostic cohort studies)/in cases (diagnostic case-control studies) 30, 33, [37] [38] [39] [42] [43] [44] [45] [46] [47] [48] 75, 76, 79, 81, 82 and seven after a negative FOBT/in controls. 30, 33, 47, 48, 75, 79, 81 Twenty-one out of 25 immunochemical FOBT studies reported using colonoscopy after a positive FOBT/in cases [52] [53] [54] [55] 57, 60, 61, [63] [64] [65] [66] [67] [68] [69] 71, 75, 76, 78, 79, 81, 82 and 16 after a negative FOBT/in controls. 52, 55, 57, 60, 61, [63] [64] [65] [66] 68, 69, 71, 75, 78, 79, 81 Where reported, other reference standards used included barium enema, sigmoidoscopy, cancer registry, follow-up, health insurance claims and re-screening. Poor reporting was a problem for many studies, particularly in relation to the information available to those interpreting tests.
Diagnostic accuracy of FOBTs
Sensitivities of guaiac FOBTs for the detection of all neoplasms (CRC and adenomas) ranged from 6.2% (Haemoccult; specificity 98.0%) 28 to 83.3% (KryptoHaem; specificity 98.4%) 35 when data were derived from diagnostic cohort studies. Diagnostic case-control studies generally reported higher sensitivities, from 47.4% (Kryptohaem; specificity 98.4%) 36 to 73.4% (Shionogi B; specificity 60.3%). 79 Sensitivities were higher for the detection of CRC (ranging from approximately 25-96% for Haemoccult, 62-79% for Haemoccult Sensa and 27% for Shionogi B), and lower for adenomas (ranging from approximately 4-19% for Haemoccult for the detection of all adenomas, and 4-33% for the detection of adenomas of 1 cm or larger). No one guaiac FOBT was consistently better than the others. Specificity was 80% or higher for all tests on all measured outcomes.
Sensitivities of immunochemical FOBTs for the detection of all neoplasms, ranged from 5.4% (OC Light; specificity 98.5%) 57 to 62.6% (Immudia HemSp; specificity 94.3%) 63 when data were derived from diagnostic cohort studies. Diagnostic case-control studies generally reported higher sensitivities, from 25.6% (MonoHaem; specificity 98.3%) 80 to 97.7% (Immudia HemSp; specificity 98.8%). 74 Immudia HemSp appeared to be the most accurate immunochemical FOBT, with sensitivities ranging from 43.3% (specificity 79.2%) 80 to 97.7% (specificity 98.8%) 74 and specificity from 77.0% (sensitivity 54.7%) 78 to 99.0% (sensitivity 80.2% 82 and 87.5% 73 ). A higher sensitivity for the detection of CRC was only apparent for OC Light (23.7-86.1%); sensitivities of immunochemical FOBTs ranged from approximately 2% (Flexsure) to 98% (MonoHaem). There was no obvious reduction in accuracy for the detection of adenomas, with sensitivities ranging from 4% (OC Light) to 63% (Immudia HemSp) for all adenomas, and 28% (Flexsure) to 67% (Immudia HemSp) for adenomas of 1 cm or larger. Specificity was 89% or higher for all named immunochemical FOBTs on all measured outcomes.
Guaiac or immunochemical?
Two diagnostic cohort studies reported direct comparisons between guaiac and immunochemical FOBTs. 75, 76 The guaiac FOBT Haemoccult Sensa was more sensitive (43.1% versus 33.1%) and less specific (90.7% versus 97.5%) than the immunochemical FOBT Flexsure for the detection of all neoplasms, but less sensitive (63.3% versus 79.1%) and less specific (90.1% versus 96.9%) for the detection of CRC in one study. 75 The other study reported Haemoccult Sensa as having the highest sensitivity for the detection of CRC (78.6%; specificity 86.7%), followed by Immudia HemSp (immunochemical) (68.2%; specificity 94.4%), and unrehydrated Haemoccult (guaiac) had the lowest sensitivity (37.5%; specificity 97.7%). 76 Eight diagnostic case-control studies reported direct comparisons. Four studies evaluated accuracy for the detection of all neoplasms; three indicated that an immunochemical FOBT had the highest sensitivity, 78, 80, 82 and all four the highest specificity. 79 For the detection of CRC, two studies reported that an immunochemical FOBT had the highest sensitivity and specificity, 81, 84 and two that a guaiac FOBT had higher sensitivity and comparable specificity. 77, 83 Therefore, immunochemical FOBTs were not consistently better than guaiac FOBTs.
With so few direct comparisons, attempts were made to draw indirect comparisons by visual inspection of the results of the diagnostic cohort studies plotted in ROC space (Figure 1 ). There was no clear indication that either guaiac or immunochemical FOBTs performed better.
We restricted indirect comparisons to diagnostic cohort studies due to the potential overestimation of accuracy in diagnostic case-control studies. 88, 89 The impact of study design can be seen in Figure 2 , where results from both diagnostic cohort and diagnostic case-control studies are plotted in ROC space. It can be seen that the sensitivity of both guaiac and immunochemical FOBTs was generally higher in diagnostic case-control studies.
DISCUSSION
In diagnostic cohort studies, KryptoHaem had the highest sensitivity of the guaiac tests for detecting all neoplasms, and non-rehydrated Haemoccult and Haemoccult Sensa for detecting CRC. However, studies from which these data were derived had limitations, including a lack of information regarding the patient spectrum, 35, 49 or use of an inappropriate reference standard (barium enema, sigmoidoscopy, or questionnaire, general practitioner contact and cancer registry). 35, 40, 49 Immudia HemSp seemed the most sensitive immunochemical FOBT for the detection of all neoplasms in the diagnostic cohort studies. 63 This test also performed more consistently than other immunochemical FOBTs for the detection of CRC, and the diagnostic cohort study evaluating Immudia HemSp was of better quality than those evaluating other immunochemical FOBTs.
The number of colonoscopies required due to differing positivity rates will be an issue for any national screening programme. If 60% of the people aged between 60 and 69 years in the UK (3,360,000 people) complied with FOBT screening, 90 the positivity rates reported in the diagnostic cohort studies in this review suggest that between 36,960 and 538,000 colonoscopies after guaiac tests, and 60,480 and 302,400 after immunochemical tests, would be required if used as a single test. These values reflect the uncertainty of the evidence available; no firm conclusions can be drawn from these data regarding the number of colonoscopies that would be required after implementation of screening and how this might vary with the type of FOBT used.
We conducted extensive literature searches, assessed study quality, included studies in any language, and attempted to maximize available data by deriving diagnostic cohorts from the intervention arms of screening studies. Few studies reported direct comparisons between FOBTs; where reported, results were inconsistent and often conflicting, though there was some indication of a better overall performance for immunochemical FOBTs. Therefore the review had to rely upon less reliable indirect comparisons, which also showed no clear evidence to suggest that either guaiac or immunochemical FOBTs performed better.
Further limitations of the current review included the more frequent use of studies of diagnostic case-control design to evaluate immunochemical FOBTs, and the more frequent publication of these results in Japanese or Chinese requiring translation, increasing the potential for data extraction errors. Diagnostic case-control studies are prone to bias and over-estimation of diagnostic accuracy, particularly when cases are people with more severe disease and controls are healthy individuals. 88, 89 When the control group is derived from patients with other diagnoses, accuracy may be under-or over-estimated, depending upon the diagnoses of the control group. 91, 92 This bias, associated with the study design, may obscure clinically significant differences between the different test methodologies. The effect of this bias was evident for Haemoccult, OC Light and Immudia HemSp, where diagnostic case-control studies reported consistently higher sensitivities than the diagnostic cohort studies.
We regarded colonoscopy as the gold standard for diagnosis; other reference standards (sigmoidoscopy, referral to a cancer registry, follow-up, re-screening) were considered inappropriate for the target condition. Sigmoidoscopy only examines the distal bowel; FOBTs tend to be better at detecting lesions in this region, therefore accuracy may be overestimated, particularly for immunochemical FOBTs which detect intact globin that may be degraded during transit from a lesion in the proximal bowel. This bias may be offset to some degree by the greater volume of bleeding from cancers of the proximal colon. 93, 94 Referral to the cancer registry and repeat screening may result in interval (false negative) results being missed, either due to loss to followup or being wrongly classified as true negative. The use of reference standards that may not identify the target condition in those with a negative FOBT could result in an underestimation of the number of false-negatives and hence an over-estimation of sensitivity. Guaiac tests are generally best at detecting large, more distal lesions. They depend upon peroxidase or pseudoperoxidase activity in faeces not specific to human haemoglobin. A number of variables may influence guaiac test results that do not influence the results of immunochemical tests. These include ingestion of animal haemoglobin/ myoglobin in red meat, fruits and vegetables high in peroxidase activity, and aspirin or other medication that may produce gastrointestinal bleeding, each of which may cause false-positive results, 95 and high doses of vitamin C 96 and faecal dehydration 97 which may cause false-negative results. Insufficient data were available to support investigation into the impact of study design, type of test, patient spectrum, reference standards used, the threshold used to define a positive result and test-specific details (e.g. rehydration and dietary restrictions for guaiac FOBTs) upon diagnostic accuracy.
Future research
Well-designed diagnostic cohort studies directly comparing guaiac and immunochemical FOBTs are required to determine the true comparative accuracy of these different testing strategies. The possible need for retesting, and impacts upon the infrastructure requirements and cost of a screening programme, particularly in relation to the number of colonoscopies that would be required in the UK, should be examined. Studies should ideally recruit a representative screening population, use colonoscopy to confirm diagnosis regardless of the FOBT result, measure the detection of CRC and adenomas and report the results separately and combined, and allow outcome assessors access to clinical information that would be available in practice, but blind them to other information.
Other areas requiring research include: the impact of dietary restrictions for guaiac FOBTs on compliance; the acceptability of different FOBTs to screenees; the impact of false-positive and false-negative results on psychiatric morbidity, future self-referral with onset of symptoms, and attendance at rescreening sessions; and the impact on accuracy of variability in the skills and experience of those conducting and interpreting tests. The availability of tests that allow automated analysis must be considered, and their impact on accuracy by removing the human factors associated with manual development of tests determined.
The standard of reporting of primary studies was a problem throughout the review and the authors recommend the use of the Standards for Reporting of Diagnostic Accuracy (STARD) checklist to improve the quality of reporting of future diagnostic studies. [98] [99] [100] 
Implications for policy
Sensitivities derived from diagnostic cohort studies were generally low, being o50% in 89% of studies for the detection of all neoplasms, and 50% of studies for the detection of CRC. Therefore the 'miss rate' is likely to be high regardless of the FOBT used, particularly when small adenomas are included in the definition of the target condition. The overall test accuracy, compliance, handling of the specimens, cost-effectiveness and availability in the UK must be considered when selecting an FOBT for use as a screening tool. Compliance may be better with immunochemical tests due to an easier collection method, less contact with the stool specimen and no requirement for dietary restrictions; there is insufficient evidence to confirm this. In contrast, immunochemical FOBTs may be more costly. There have also been concerns raised in the UK relating to the postal service handling immunochemical FOBTs. However, when the Australian screening programme was introduced, approval was granted for the transfer of immunochemical tests via the postal service.
Addendum
The search in March 2007 identified two further studies that met the inclusion criteria. 86, 87 One was a diagnostic cohort study in which 3090 patients underwent colonoscopy and an unspecified immunochemical FOBT. For the detection of all neoplasms, sensitivity was 53% and specificity 99.6%; for the detection of CRC, sensitivity was 52.6% and specificity 87.2%. 86 The other was a diagnostic case-control study in which 57 people with a diagnosis of cancer and 44 volunteer controls underwent a guaiac FOBT; sensitivity was 51% and specificity 98%. 87 These results are comparable with those of other studies of similar design included in the review, and do not alter the conclusions.
